{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:48:06Z","timestamp":1773384486716,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Institute","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR003098"],"award-info":[{"award-number":["UL1TR003098"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["S10RR026824"],"award-info":[{"award-number":["S10RR026824"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD103124"],"award-info":[{"award-number":["R01HD103124"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD108905"],"award-info":[{"award-number":["R01HD108905"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023581","name":"National Science Foundation Graduate Research Fellowship Program","doi-asserted-by":"publisher","award":["National Science Foundation Graduate Research Fellowship Program"],"award-info":[{"award-number":["National Science Foundation Graduate Research Fellowship Program"]}],"id":[{"id":"10.13039\/100023581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023581","name":"National Science Foundation Graduate Research Fellowship Program","doi-asserted-by":"publisher","award":["National Science Foundation Graduate Research Fellowship Program"],"award-info":[{"award-number":["National Science Foundation Graduate Research Fellowship Program"]}],"id":[{"id":"10.13039\/100023581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006792","name":"Hartwell Foundation","doi-asserted-by":"publisher","award":["Hartwell Foundation"],"award-info":[{"award-number":["Hartwell Foundation"]}],"id":[{"id":"10.13039\/100006792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13346-024-01618-6","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T14:02:57Z","timestamp":1715781777000},"page":"609-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Locally administered nanosuspension increases delivery of estradiol for the treatment of vaginal atrophy in mice"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-8278","authenticated-orcid":false,"given":"Rachel L.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0818-3848","authenticated-orcid":false,"given":"Titania","family":"Bethiana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6905-1277","authenticated-orcid":false,"given":"Davell M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9465-3373","authenticated-orcid":false,"given":"Jairo","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8710-9601","authenticated-orcid":false,"given":"Kevin","family":"DeLong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tricia A.","family":"Numan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4285-1618","authenticated-orcid":false,"given":"Hannah C.","family":"Zierden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6949-7911","authenticated-orcid":false,"given":"Laura M.","family":"Ensign","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"issue":"1","key":"1618_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4065\/mcp.2009.0413","volume":"85","author":"MB Mac Bride","year":"2010","unstructured":"Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87\u201394.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1618_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13697137.2018.1529748","volume":"22","author":"A Cagnacci","year":"2019","unstructured":"Cagnacci A, et al. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric. 2019;22(1):85\u20139.","journal-title":"Climacteric"},{"issue":"2","key":"1618_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/sm2.17","volume":"1","author":"I Goldstein","year":"2013","unstructured":"Goldstein I, et al. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med. 2013;1(2):44\u201353.","journal-title":"Sex Med"},{"issue":"3","key":"1618_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/13697137.2018.1551871","volume":"22","author":"C Jung","year":"2019","unstructured":"Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric. 2019;22(3):242\u20139.","journal-title":"Climacteric"},{"key":"1618_CR5","unstructured":"Bleibel B, Nguyen H. Vaginal atrophy, in StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Hao Nguyen declares no relevant financial relationships with ineligible companies. 2023."},{"key":"1618_CR6","doi-asserted-by":"crossref","unstructured":"Palacios S. Ospemifene for vulvar and vaginal atrophy: an overview. Drugs Context, 2020;9.","DOI":"10.7573\/dic.2020-3-2"},{"key":"1618_CR7","doi-asserted-by":"crossref","unstructured":"Benini V et al. New innovations for the treatment of Vulvovaginal Atrophy: an Up-to-date review. Med (Kaunas), 2022;58(6).","DOI":"10.3390\/medicina58060770"},{"issue":"5","key":"1618_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.molmed.2020.12.001","volume":"27","author":"HC Zierden","year":"2021","unstructured":"Zierden HC, et al. Avoiding a Sticky Situation: bypassing the mucus barrier for Improved Local Drug Delivery. Trends Mol Med. 2021;27(5):436\u201350.","journal-title":"Trends Mol Med"},{"issue":"2","key":"1618_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1073\/pnas.0911748107","volume":"107","author":"SK Lai","year":"2010","unstructured":"Lai SK, et al. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci U S A. 2010;107(2):598\u2013603.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1618_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jconrel.2018.12.046","volume":"295","author":"T Hoang","year":"2019","unstructured":"Hoang T, et al. Development of a mucoinert progesterone nanosuspension for safer and more effective prevention of preterm birth. J Control Release. 2019;295:74\u201386.","journal-title":"J Control Release"},{"issue":"21","key":"1618_CR11","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/adhm.201600599","volume":"5","author":"T Yu","year":"2016","unstructured":"Yu T, et al. Mucus-penetrating nanosuspensions for enhanced delivery of poorly soluble drugs to Mucosal surfaces. Adv Healthc Mater. 2016;5(21):2745\u201350.","journal-title":"Adv Healthc Mater"},{"issue":"138","key":"1618_CR12","doi-asserted-by":"publisher","first-page":"138ra79","DOI":"10.1126\/scitranslmed.3003453","volume":"4","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4(138):138ra79.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1618_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/adhm.201300519","volume":"3","author":"M Yang","year":"2014","unstructured":"Yang M, et al. Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater. 2014;3(7):1044\u201352.","journal-title":"Adv Healthc Mater"},{"key":"1618_CR14","doi-asserted-by":"crossref","unstructured":"Zierden HC et al. Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of preterm birth. Sci Transl Med, 2021;13(576).","DOI":"10.1126\/scitranslmed.abc6245"},{"issue":"28","key":"1618_CR15","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1016\/j.biomaterials.2013.05.039","volume":"34","author":"LM Ensign","year":"2013","unstructured":"Ensign LM, et al. Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. Biomaterials. 2013;34(28):6922\u20139.","journal-title":"Biomaterials"},{"key":"1618_CR16","unstructured":"Clinic M. Drugs and Supplements. Estradiol (Vaginal Route) 2023."},{"issue":"11","key":"1618_CR17","doi-asserted-by":"publisher","first-page":"e48328","DOI":"10.1371\/journal.pone.0048328","volume":"7","author":"CS Dezzutti","year":"2012","unstructured":"Dezzutti CS, et al. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS ONE. 2012;7(11):e48328.","journal-title":"PLoS ONE"},{"key":"1618_CR18","doi-asserted-by":"crossref","unstructured":"Strom JO et al. Ovariectomy and 17beta-estradiol replacement in rats and mice: a visual demonstration. J Vis Exp, 2012(64): p. e4013.","DOI":"10.3791\/4013"},{"issue":"4","key":"1618_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.maturitas.2015.05.010","volume":"81","author":"JD Illston","year":"2015","unstructured":"Illston JD, et al. Low-dose 17-beta-estradiol cream for vaginal atrophy in a cohort without prolapse: serum levels and vaginal response including tissue biomarkers associated with tissue remodeling. Maturitas. 2015;81(4):475\u20139.","journal-title":"Maturitas"},{"issue":"10","key":"1618_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/gme.0b013e3182518e9a","volume":"19","author":"A Cano","year":"2012","unstructured":"Cano A, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause. 2012;19(10):1130\u20139.","journal-title":"Menopause"},{"issue":"2","key":"1618_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ajpath.2019.10.013","volume":"190","author":"HC Zierden","year":"2020","unstructured":"Zierden HC, et al. Characterization of an adapted murine model of intrauterine inflammation-Induced Preterm Birth. Am J Pathol. 2020;190(2):295\u2013305.","journal-title":"Am J Pathol"},{"key":"1618_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jconrel.2014.04.033","volume":"190","author":"LM Ensign","year":"2014","unstructured":"Ensign LM, Cone R, Hanes J. Nanoparticle-based drug delivery to the vagina: a review. J Control Release. 2014;190:500\u201314.","journal-title":"J Control Release"},{"issue":"10","key":"1618_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S1461-5347(00)00296-0","volume":"3","author":"K Vermani","year":"2000","unstructured":"Vermani K, Garg S. The scope and potential of vaginal drug delivery. Pharm Sci Technol Today. 2000;3(10):359\u201364.","journal-title":"Pharm Sci Technol Today"},{"key":"1618_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fmed.2017.00101","volume":"4","author":"T Marichal","year":"2017","unstructured":"Marichal T, Mesnil C, Bureau F. Homeostatic eosinophils: characteristics and functions. Front Med (Lausanne). 2017;4:101.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1618_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1095\/biolreprod54.1.249","volume":"54","author":"MC Perez","year":"1996","unstructured":"Perez MC, et al. Role of eosinophils in uterine responses to estrogen. Biol Reprod. 1996;54(1):249\u201354.","journal-title":"Biol Reprod"},{"issue":"1","key":"1618_CR26","doi-asserted-by":"publisher","first-page":"e8659","DOI":"10.1590\/1414-431x20198659","volume":"53","author":"JMD Araujo","year":"2020","unstructured":"Araujo JMD, et al. CCR3 antagonist impairs estradiol-induced eosinophil migration to the uterus in ovariectomized mice. Braz J Med Biol Res. 2020;53(1):e8659.","journal-title":"Braz J Med Biol Res"},{"issue":"6","key":"1618_CR27","first-page":"2223","volume":"150","author":"JS Griffith","year":"1997","unstructured":"Griffith JS, et al. Evidence for the genetic control of estradiol-regulated responses. Implications for variation in normal and pathological hormone-dependent phenotypes. Am J Pathol. 1997;150(6):2223\u201330.","journal-title":"Am J Pathol"},{"key":"1618_CR28","unstructured":"Aging NIo., editor. What is menopause? 2021."},{"key":"1618_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1210\/rp.57.1.257","volume":"57","author":"HG Burger","year":"2002","unstructured":"Burger HG, et al. Hormonal changes in the menopause transition. Recent Prog Horm Res. 2002;57:257\u201375.","journal-title":"Recent Prog Horm Res"},{"issue":"17","key":"1618_CR30","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1161\/CIRCULATIONAHA.105.551341","volume":"112","author":"RC Becker","year":"2005","unstructured":"Becker RC. Cardiology patient page. Heart attack and stroke prevention in women. Circulation. 2005;112(17):e273\u20135.","journal-title":"Circulation"},{"issue":"2","key":"1618_CR31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1210\/jc.2014-3062","volume":"100","author":"CJ Crandall","year":"2015","unstructured":"Crandall CJ, et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab. 2015;100(2):524\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1618_CR32","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1289\/ehp.1002158","volume":"118","author":"LW Jackson","year":"2010","unstructured":"Jackson LW, Cromer BA, Panneerselvamm A. Association between bone turnover, micronutrient intake, and blood lead levels in pre- and postmenopausal women, NHANES 1999\u20132002. Environ Health Perspect. 2010;118(11):1590\u20136.","journal-title":"Environ Health Perspect"},{"issue":"10","key":"1618_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/GME.0000000000000319","volume":"21","author":"JL Shifren","year":"2014","unstructured":"Shifren JL, Gass ML. N.R.f.C.C.o.M.W.W. Group, the North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038\u201362.","journal-title":"Menopause"},{"issue":"10","key":"1618_CR34","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/archinte.159.10.1061","volume":"159","author":"FB Hu","year":"1999","unstructured":"Hu FB, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med. 1999;159(10):1061\u20136.","journal-title":"Arch Intern Med"},{"key":"1618_CR35","doi-asserted-by":"publisher","first-page":"114543","DOI":"10.1016\/j.addr.2022.114543","volume":"191","author":"RL Shapiro","year":"2022","unstructured":"Shapiro RL, et al. In vitro and ex vivo models for evaluating vaginal drug delivery systems. Adv Drug Deliv Rev. 2022;191:114543.","journal-title":"Adv Drug Deliv Rev"},{"key":"1618_CR36","unstructured":"DailyMed NLoM. Label: Estrace - estradiol cream. 2022."},{"key":"1618_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/1471-2334-10-331","volume":"10","author":"TR Moench","year":"2010","unstructured":"Moench TR, et al. Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect Dis. 2010;10:331.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1618_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/GME.0000000000000985","volume":"25","author":"R Kroll","year":"2018","unstructured":"Kroll R, et al. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. Menopause. 2018;25(2):133\u20138.","journal-title":"Menopause"},{"issue":"4","key":"1618_CR39","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/cpt1979264502","volume":"26","author":"J Dickerson","year":"1979","unstructured":"Dickerson J, et al. Efficacy of estradiol vaginal cream in postmenopausal women. Clin Pharmacol Ther. 1979;26(4):502\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1618_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/13697130500087016","volume":"8","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8(1):83\u201392.","journal-title":"Climacteric"},{"issue":"1","key":"1618_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0378-5122(96)01072-9","volume":"26","author":"HA Nash","year":"1997","unstructured":"Nash HA, et al. Estradiol delivery by vaginal rings: potential for hormone replacement therapy. Maturitas. 1997;26(1):27\u201333.","journal-title":"Maturitas"},{"issue":"4","key":"1618_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/ejc.8.4.217.224","volume":"8","author":"NN Sarkar","year":"2003","unstructured":"Sarkar NN. Low-dose intravaginal estradiol delivery using a silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review. Eur J Contracept Reprod Health Care. 2003;8(4):217\u201324.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"5","key":"1618_CR43","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1016\/S0002-9378(98)70558-7","volume":"178","author":"GA Bachmann","year":"1998","unstructured":"Bachmann GA. The clinical platform for the 17beta-estradiol vaginal releasing ring. Am J Obstet Gynecol. 1998;178(5):S257\u201360.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1618_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/00042192-200007030-00005","volume":"7","author":"JE Rioux","year":"2000","unstructured":"Rioux JE, et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000;7(3):156\u201361.","journal-title":"Menopause"},{"issue":"Suppl","key":"1618_CR45","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/0378-5122(95)00963-9","volume":"22","author":"LE Nachtigall","year":"1995","unstructured":"LE Nachtigall. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas. 1995;22(Suppl):S43\u20137.","journal-title":"Maturitas"},{"issue":"3","key":"1618_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/13697137.2010.483297","volume":"13","author":"M Eugster-Hausmann","year":"2010","unstructured":"Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010;13(3):219\u201327.","journal-title":"Climacteric"},{"issue":"1","key":"1618_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/01.AOG.0000296714.12226.0f","volume":"111","author":"G Bachmann","year":"2008","unstructured":"Bachmann G, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111(1):67\u201376.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"1618_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17425247.2020.1728251","volume":"17","author":"T Fernandes","year":"2020","unstructured":"Fernandes T, et al. Vaginal multipurpose prevention technologies: promising approaches for enhancing women\u2019s sexual and reproductive health. Expert Opin Drug Deliv. 2020;17(3):379\u201393.","journal-title":"Expert Opin Drug Deliv"},{"key":"1618_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.33393\/dti.2023.2477","volume":"17","author":"IZ Abidin","year":"2023","unstructured":"Abidin IZ, et al. A systematic review of mucoadhesive vaginal tablet testing. Drug Target Insights. 2023;17:5\u201330.","journal-title":"Drug Target Insights"},{"issue":"11","key":"1618_CR50","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1080\/17425247.2020.1798927","volume":"17","author":"P Boyd","year":"2020","unstructured":"Boyd P, et al. The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals. Expert Opin Drug Deliv. 2020;17(11):1519\u201340.","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"1618_CR51","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.contraception.2010.04.012","volume":"82","author":"V Brache","year":"2010","unstructured":"Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010;82(5):418\u201327.","journal-title":"Contraception"},{"key":"1618_CR52","doi-asserted-by":"publisher","first-page":"114133","DOI":"10.1016\/j.addr.2022.114133","volume":"182","author":"R Palmeira-de-Oliveira","year":"2022","unstructured":"Palmeira-de-Oliveira R, et al. Women\u2019s preferences and acceptance for different drug delivery routes and products. Adv Drug Deliv Rev. 2022;182:114133.","journal-title":"Adv Drug Deliv Rev"},{"key":"1618_CR53","doi-asserted-by":"crossref","unstructured":"Carson L et al. The vaginal microbiota, bacterial biofilms and Polymeric Drug-releasing Vaginal rings. Pharmaceutics, 2021;13(5).","DOI":"10.3390\/pharmaceutics13050751"},{"key":"1618_CR54","doi-asserted-by":"crossref","unstructured":"Abou-Taleb HA et al. Chitosan\/Solid-Lipid Nanoparticles Hybrid Gels for vaginal delivery of Estradiol for Management of Vaginal menopausal symptoms. Pharmaceuticals (Basel), 2023;16(9).","DOI":"10.3390\/ph16091284"},{"issue":"1","key":"1618_CR55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/03639045.2019.1711386","volume":"46","author":"RM Machado","year":"2020","unstructured":"Machado RM, et al. The vaginal sheet: an innovative form of vaginal film for the treatment of vaginal infections. Drug Dev Ind Pharm. 2020;46(1):135\u201345.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"1618_CR56","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejps.2012.06.001","volume":"47","author":"WZ Li","year":"2012","unstructured":"Li WZ, et al. Post-expansile hydrogel foam aerosol of PG-liposomes: a novel delivery system for vaginal drug delivery applications. Eur J Pharm Sci. 2012;47(1):162\u20139.","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"1618_CR57","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/jps.23577","volume":"102","author":"RM Machado","year":"2013","unstructured":"Machado RM, et al. Vaginal films for drug delivery. J Pharm Sci. 2013;102(7):2069\u201381.","journal-title":"J Pharm Sci"},{"key":"1618_CR58","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jconrel.2020.08.032","volume":"327","author":"F Notario-Perez","year":"2020","unstructured":"Notario-Perez F, et al. Design, fabrication and characterisation of drug-loaded vaginal films: state-of-the-art. J Control Release. 2020;327:477\u201399.","journal-title":"J Control Release"},{"issue":"6","key":"1618_CR59","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/03639045.2020.1767125","volume":"46","author":"F Tugcu-Demiroz","year":"2020","unstructured":"Tugcu-Demiroz F, et al. Electrospun metronidazole-loaded nanofibers for vaginal drug delivery. Drug Dev Ind Pharm. 2020;46(6):1015\u201325.","journal-title":"Drug Dev Ind Pharm"},{"key":"1618_CR60","doi-asserted-by":"publisher","first-page":"105563","DOI":"10.1016\/j.ejps.2020.105563","volume":"156","author":"JA Silva","year":"2021","unstructured":"Silva JA, et al. Immobilization of vaginal Lactobacillus in polymeric nanofibers for its incorporation in vaginal probiotic products. Eur J Pharm Sci. 2021;156:105563.","journal-title":"Eur J Pharm Sci"},{"key":"1618_CR61","doi-asserted-by":"publisher","first-page":"213614","DOI":"10.1016\/j.bioadv.2023.213614","volume":"154","author":"F Minooei","year":"2023","unstructured":"Minooei F, et al. Mesh and layered electrospun fiber architectures as vehicles for Lactobacillus acidophilus and Lactobacillus crispatus intended for vaginal delivery. Biomater Adv. 2023;154:213614.","journal-title":"Biomater Adv"},{"key":"1618_CR62","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejpb.2023.07.009","volume":"190","author":"F Minooei","year":"2023","unstructured":"Minooei F, et al. Rapid-dissolving electrospun nanofibers for intra-vaginal antibiotic or probiotic delivery. Eur J Pharm Biopharm. 2023;190:81\u201393.","journal-title":"Eur J Pharm Biopharm"},{"key":"1618_CR63","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejpb.2023.04.011","volume":"187","author":"MY Mahmoud","year":"2023","unstructured":"Mahmoud MY, et al. Lactobacillus crispatus-loaded electrospun fibers yield viable and metabolically active bacteria that kill Gardnerella in vitro. Eur J Pharm Biopharm. 2023;187:68\u201375.","journal-title":"Eur J Pharm Biopharm"},{"key":"1618_CR64","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jconrel.2023.04.023","volume":"357","author":"AJ Kyser","year":"2023","unstructured":"Kyser AJ, et al. Fabrication and characterization of bioprints with Lactobacillus crispatus for vaginal application. J Control Release. 2023;357:545\u201360.","journal-title":"J Control Release"},{"key":"1618_CR65","doi-asserted-by":"publisher","first-page":"112523","DOI":"10.1016\/j.msec.2021.112523","volume":"131","author":"F Corduas","year":"2021","unstructured":"Corduas F, et al. Melt-extrusion 3D printing of resorbable levofloxacin-loaded meshes: emerging strategy for urogynaecological applications. Mater Sci Eng C Mater Biol Appl. 2021;131:112523.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"1618_CR66","doi-asserted-by":"publisher","first-page":"121040","DOI":"10.1016\/j.ijpharm.2021.121040","volume":"607","author":"R Cazorla-Luna","year":"2021","unstructured":"Cazorla-Luna R, et al. Recent advances in electrospun nanofiber vaginal formulations for women\u2019s sexual and reproductive health. Int J Pharm. 2021;607:121040.","journal-title":"Int J Pharm"},{"issue":"8","key":"1618_CR67","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","volume":"94","author":"T Key","year":"2002","unstructured":"Key T, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1618_CR68","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bjc.2011.254","volume":"105","author":"H Endogenous","year":"2011","unstructured":"Endogenous H, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105(5):709\u201322.","journal-title":"Br J Cancer"},{"key":"1618_CR69","unstructured":"LLC PUC. ESTRING- estradiol system Physician\u2019s Leaflet. 2022."},{"issue":"4","key":"1618_CR70","doi-asserted-by":"publisher","first-page":"e35538","DOI":"10.1371\/journal.pone.0035538","volume":"7","author":"SL Byers","year":"2012","unstructured":"Byers SL, et al. Mouse estrous cycle identification tool and images. PLoS ONE. 2012;7(4):e35538.","journal-title":"PLoS ONE"},{"issue":"2","key":"1618_CR71","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1753425912454026","volume":"19","author":"DK Hickey","year":"2013","unstructured":"Hickey DK, Fahey JV, Wira CR. Mouse estrous cycle regulation of vaginal versus uterine cytokines, chemokines, alpha-\/beta-defensins and TLRs. Innate Immun. 2013;19(2):121\u201331.","journal-title":"Innate Immun"},{"issue":"7","key":"1618_CR72","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1128\/IAI.68.7.4207-4216.2000","volume":"68","author":"C Kaushic","year":"2000","unstructured":"Kaushic C, et al. Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect Immun. 2000;68(7):4207\u201316.","journal-title":"Infect Immun"},{"issue":"5","key":"1618_CR73","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1128\/JVI.79.5.3107-3116.2005","volume":"79","author":"AE Gillgrass","year":"2005","unstructured":"Gillgrass AE, et al. Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation. J Virol. 2005;79(5):3107\u201316.","journal-title":"J Virol"},{"key":"1618_CR74","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2334-6-90","volume":"6","author":"RA Cone","year":"2006","unstructured":"Cone RA, et al. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis. 2006;6:90.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1618_CR75","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1097\/SPV.0000000000000790","volume":"27","author":"MR Meister","year":"2021","unstructured":"Meister MR, et al. Vaginal estrogen therapy is Associated with decreased inflammatory response in Postmenopausal Women with recurrent urinary tract infections. Female Pelvic Med Reconstr Surg. 2021;27(1):e39\u201344.","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"7","key":"1618_CR76","doi-asserted-by":"publisher","first-page":"e1002149","DOI":"10.1371\/journal.ppat.1002149","volume":"7","author":"DP Robinson","year":"2011","unstructured":"Robinson DP, et al. Elevated 17beta-estradiol protects females from influenza a virus pathogenesis by suppressing inflammatory responses. PLoS Pathog. 2011;7(7):e1002149.","journal-title":"PLoS Pathog"},{"issue":"1","key":"1618_CR77","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12866-018-1341-2","volume":"18","author":"A Vrbanac","year":"2018","unstructured":"Vrbanac A, et al. The murine vaginal microbiota and its perturbation by the human pathogen group B Streptococcus. BMC Microbiol. 2018;18(1):197.","journal-title":"BMC Microbiol"},{"key":"1618_CR78","doi-asserted-by":"crossref","unstructured":"Miller EA et al. Lactobacilli Dominance and Vaginal pH: Why Is the Human Vaginal Microbiome Unique? Front Microbiol, 2016. 7: p. 1936.","DOI":"10.3389\/fmicb.2016.01936"},{"issue":"4","key":"1618_CR79","doi-asserted-by":"publisher","first-page":"e0128622","DOI":"10.1128\/spectrum.01286-22","volume":"10","author":"JM Greenberg","year":"2022","unstructured":"Greenberg JM, et al. Microbiota of the pregnant mouse: characterization of the bacterial communities in the oral cavity, lung, intestine, and Vagina through Culture and DNA sequencing. Microbiol Spectr. 2022;10(4):e0128622.","journal-title":"Microbiol Spectr"},{"key":"1618_CR80","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/1471-2180-13-303","volume":"13","author":"KK Barfod","year":"2013","unstructured":"Barfod KK, et al. The murine lung microbiome in relation to the intestinal and vaginal bacterial communities. BMC Microbiol. 2013;13:303.","journal-title":"BMC Microbiol"},{"key":"1618_CR81","doi-asserted-by":"crossref","unstructured":"Heiss HMCGS. Changes in vaginal bacterial Flora during the Oestrous cycle of the mouse. Microb Ecol Health Disease, 1991. 4, 1991(4).","DOI":"10.3402\/mehd.v4i4.7689"},{"key":"1618_CR82","doi-asserted-by":"crossref","unstructured":"Miao J, Willems HME, Peters BM. Exogenous Reproductive hormones nor Candida albicans colonization alter the Near Neutral Mouse Vaginal pH. Infect Immun, 2021;89(2).","DOI":"10.1128\/IAI.00550-20"},{"key":"1618_CR83","doi-asserted-by":"crossref","unstructured":"Park MG, Cho S, Oh MM. Menopausal changes in the Microbiome-A Review focused on the Genitourinary Microbiome. Diagnostics (Basel), 2023;13(6).","DOI":"10.3390\/diagnostics13061193"},{"key":"1618_CR84","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.maturitas.2016.05.015","volume":"91","author":"AL Muhleisen","year":"2016","unstructured":"Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. 2016;91:42\u201350.","journal-title":"Maturitas"},{"issue":"4","key":"1618_CR85","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1128\/CMR.4.4.485","volume":"4","author":"CA Spiegel","year":"1991","unstructured":"Spiegel CA. Bacterial vaginosis. Clin Microbiol Rev. 1991;4(4):485\u2013502.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"1618_CR86","doi-asserted-by":"publisher","first-page":"e1008236","DOI":"10.1371\/journal.ppat.1008236","volume":"16","author":"T Hoang","year":"2020","unstructured":"Hoang T, et al. The cervicovaginal mucus barrier to HIV-1 is diminished in bacterial vaginosis. PLoS Pathog. 2020;16(1):e1008236.","journal-title":"PLoS Pathog"},{"issue":"12","key":"1618_CR87","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s10995-015-1790-2","volume":"19","author":"DB Nelson","year":"2015","unstructured":"Nelson DB, et al. First trimester levels of BV-Associated Bacteria and risk of Miscarriage among women early in pregnancy. Matern Child Health J. 2015;19(12):2682\u20137.","journal-title":"Matern Child Health J"},{"issue":"1","key":"1618_CR88","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12884-016-1073-y","volume":"16","author":"AS Dingens","year":"2016","unstructured":"Dingens AS, et al. Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC Pregnancy Childbirth. 2016;16(1):278.","journal-title":"BMC Pregnancy Childbirth"},{"key":"1618_CR89","first-page":"303","volume-title":"Comparative anatomy and histology (Second Edition): a mouse, rat, and human Atlas","author":"L Kelli","year":"2018","unstructured":"Kelli L, Boyd AM, Mara H, Rendi RL, Garcia, Katherine N, Gibson-Corley. Female Reproductive System. In: Piper SMD, Treuting M, Montine KS, editors. Comparative anatomy and histology (2nd ed): a mouse, rat, and human Atlas. Editor: Elsevier; 2018. pp. 303\u201334."},{"key":"1618_CR90","first-page":"253","volume-title":"Comparative anatomy and histology: a mouse and human Atlas","author":"H Mara","year":"2012","unstructured":"Mara H, Rendi AM, Rochelle L, Garcia KL, Boyd. Female Reproductive System. In: Piper SMD, Treuting M, editors. Comparative anatomy and histology: a mouse and human Atlas. Editor: Elsevier Inc; 2012. pp. 253\u201384."},{"key":"1618_CR91","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.diff.2019.07.004","volume":"110","author":"GR Cunha","year":"2019","unstructured":"Cunha GR, et al. Reproductive tract biology: of mice and men. Differentiation. 2019;110:49\u201363.","journal-title":"Differentiation"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01618-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01618-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01618-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:04:54Z","timestamp":1735517094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01618-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01618-6","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"1 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Johns Hopkins program of Animal care and Use is accredited by AAALAC international. Animal care, and procedures follow the Guide for the Care and Use of Laboratory Animals 8th ed. All experimental protocols involving mice were approved by the Johns Hopkins Animal Care and Use Committee. Unless otherwise specified, CD-1 mice were ordered from Charles River Laboratories at 6\u20138 weeks and were housed in a satellite housing facility in cages of 5 mice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No human materials or subjects were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The mucus-penetrating particle technology is licensed and in clinical development for ocular indications by Kala Pharmaceuticals. Under a licensing agreement between Kala Pharmaceuticals and the Johns Hopkins University, Laura M. Ensign and the University are entitled to royalty distributions related to the technology. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}